Clinical Trials Liability

1. Meaning

Clinical Trials Liability refers to the legal responsibility of sponsors, pharmaceutical companies, investigators, hospitals, research institutions, contract research organizations (CROs), ethics committees, physicians and other participants in a clinical trial for injury, death, inadequate informed consent, negligence, protocol violations, research misconduct, failure to disclose risks, defective investigational products, or other unlawful conduct connected with the trial.

Clinical-trial liability is different from ordinary medical malpractice because the participant may be exposed to an experimental intervention whose safety and efficacy are not yet fully established.

The central legal question is:

When a person voluntarily participates in medical research and suffers harm, when should the risk be treated as an accepted research risk, and when should the sponsor, investigator, institution or manufacturer be legally responsible?

The answer depends upon the applicable statute, consent documents, trial protocol, regulatory requirements, negligence principles, product-liability rules and compensation framework.

2. Why Clinical-Trial Liability Is Special

A normal doctor-patient relationship is primarily therapeutic.

A clinical trial has a different structure:

Sponsor

↓

Investigator / Research Institution

↓

Ethics Committee / IRB

↓

Clinical Research Organization

↓

Trial Participant

Several parties may therefore bear different legal responsibilities.

For example:

• the sponsor may be responsible for compensation and trial design;
• the investigator may be responsible for informed consent and participant safety;
• the hospital may be responsible for institutional conduct;
• the CRO may be responsible for delegated trial functions;
• the manufacturer may face product-liability claims;
• the ethics committee may face liability depending upon applicable law and its role.

3. Major Forms of Clinical-Trial Liability

A. Failure of Informed Consent

A participant must understand material information concerning:

• experimental nature of the trial;
• purpose;
• procedures;
• foreseeable risks;
• potential benefits;
• alternatives;
• confidentiality;
• compensation;
• medical treatment available for research-related injury.

The FDA's informed-consent framework specifically requires disclosure of the research nature, procedures, reasonably foreseeable risks, expected benefits and, for greater-than-minimal-risk research, information concerning compensation and medical treatment for research-related injury.

B. Negligent Trial Design

A sponsor or investigator may face liability where the study itself is designed in an unreasonably dangerous manner.

Examples:

• unnecessary exposure to known risks;
• inadequate exclusion criteria;
• inappropriate dosage;
• inadequate monitoring;
• failure to establish stopping rules;
• failure to respond to emerging safety signals.

C. Negligent Monitoring

A trial may become dangerous because investigators fail to monitor participants adequately.

Examples:

• failure to perform required laboratory tests;
• failure to investigate abnormal results;
• failure to report adverse events;
• failure to suspend the trial after serious safety signals.

D. Protocol Violations

A clinical trial must ordinarily be conducted according to the approved protocol.

Liability may arise where investigators:

• deviate from the protocol;
• administer incorrect dosages;
• enroll ineligible subjects;
• fail to follow monitoring requirements;
• use an unauthorized procedure.

Indian regulations expressly recognize protocol violation, scientific misconduct or negligence by the sponsor or investigator as circumstances capable of making an injury or death “clinical-trial related” for compensation purposes.

4. Failure to Disclose Experimental Nature

A particularly serious problem occurs where a physician presents an experimental intervention as if it were established treatment.

A participant may believe:

“I am receiving accepted medical treatment.”

when in reality:

“I am participating in research whose safety and effectiveness remain uncertain.”

The distinction can affect informed-consent liability substantially.

5. Major Case Laws

1. Grimes v. Kennedy Krieger Institute, Inc., 782 A.2d 807 (Md. 2001)

This is one of the most important clinical-research liability cases.

Facts

The Kennedy Krieger Institute conducted a research project involving children living in homes affected by lead contamination.

The study examined lead-abatement measures.

The plaintiffs alleged that children were exposed to dangerous levels of lead during the research and that their parents had not been adequately informed about the risks.

Issue

Could a research institution owe a legal duty to research participants even though the activity was scientific research rather than ordinary medical treatment?

Decision

The Maryland Court of Appeals held that the research relationship could create a special relationship and corresponding legal duties.

The court found that the consent documents could also constitute a contractual relationship.

Most importantly, the court concluded that the consent was potentially inadequate because material risks had not been sufficiently disclosed.

Principle

Human-subject research can create legally enforceable duties independent of ordinary doctor-patient malpractice.

Importance

The case is important for:

• informed consent;
• researcher duties;
• negligence;
• research contracts;
• vulnerable participants;
• continuing disclosure of newly identified risks.

6. Goodman v. United States, 298 F.3d 1048 (9th Cir. 2002)

Facts

JoAnn Goodman received an experimental treatment for liver cancer.

She subsequently died.

Her estate brought claims against the United States, including an informed-consent claim.

Decision

The Ninth Circuit addressed the distinction between:

1. injury resulting from negligent treatment; and
2. injury resulting from a disclosed risk of experimental treatment.

The evidence indicated that the fatal complication was a known and disclosed risk rather than negligent conduct by the treating physicians.

Principle

An adverse outcome does not automatically establish clinical-trial negligence.

If:

• the risk was adequately disclosed;
• the participant voluntarily accepted it;
• the researchers acted within the appropriate standard of care;

the mere realization of the disclosed risk may not establish liability.

Importance

This is a critical defense principle in clinical-trial litigation.

Bad outcome ≠ automatic negligence.

7. Lewis v. Moore, 843 F.3d 229 (11th Cir. 2018)

Facts

Premature infants participated in a clinical study while receiving medical treatment.

The plaintiffs alleged injuries arising from the study and asserted claims including:

• negligence;
• negligence per se;
• breach of fiduciary duty;
• products liability;
• lack of informed consent.

Defendants included the physician who designed and conducted the study, IRB physicians, and the manufacturer of medical equipment used in the research.

Importance

The case illustrates that clinical-trial litigation may involve multiple defendants performing different roles.

A participant may therefore bring different theories against:

• investigator;
• IRB personnel;
• manufacturer;
• institution.

Legal significance

It demonstrates that clinical-trial liability cannot always be reduced to a simple doctor-patient malpractice claim.

The court must examine:

• who designed the study;
• who administered it;
• who approved it;
• who manufactured the equipment;
• what duty each defendant owed.

8. Slater v. Optical Radiation Corp., 961 F.2d 1330 (7th Cir. 1992)

Facts

Albert Slater underwent an experimental intraocular-lens procedure.

The consent form explained that the procedure was experimental and described the relevant risks.

The experimental treatment ultimately produced problems.

Decision

The Seventh Circuit emphasized that experimental treatment necessarily involves uncertainty.

Where the risks and experimental nature are adequately explained and the participant voluntarily chooses the procedure, the subsequent realization of those risks does not automatically create tort liability.

Principle

Properly disclosed experimental risk is different from undisclosed or negligently created risk.

Importance

The case demonstrates the importance of the informed-consent document in clinical-trial litigation.

It also recognizes a broader policy concern: excessive retrospective liability could discourage legitimate medical experimentation.

9. Ward v. Schaefer, 91 F.4th 947 (1st Cir. 2024)

Facts

Edmund Ward suffered from a rare genetic deficiency and participated in an experimental enzyme-therapy protocol.

His estate alleged that the physician:

• fraudulently induced participation;
• failed to obtain informed consent.

Decision

A jury found in favor of the physician, and the First Circuit affirmed.

The appellate court found no reversible error in the district court's handling of the evidence.

Principle

Participation in an experimental treatment does not itself establish liability.

The claimant still must prove the relevant elements, such as:

• inadequate disclosure;
• fraudulent inducement;
• negligence;
• causation.

Importance

The case illustrates the evidentiary difficulties faced by plaintiffs alleging that participation in experimental treatment was improperly induced.

10. Dinerstein v. Google LLC, 73 F.4th 502 (7th Cir. 2023)

Although primarily a clinical-data case rather than a physical-injury case, it is important to modern clinical-trial liability.

Facts

The University of Chicago Medical Center provided allegedly de-identified patient medical records to Google for machine-learning research.

A patient challenged the arrangement.

Issue

The litigation involved:

• medical-data use;
• research;
• contractual obligations;
• privacy;
• secondary use of clinical information.

Decision

The Seventh Circuit rejected the plaintiff's contractual theory.

Importance

The case demonstrates that modern clinical-research liability is not limited to physical injuries.

It can also involve:

• unauthorized secondary research;
• clinical-data commercialization;
• AI;
• privacy;
• data-use agreements.

11. Kus v. Sherman Hospital, 268 Ill. App. 3d 771 (1994)

Facts

A patient received an experimental intraocular lens.

The patient alleged that the consent form had been modified and failed to disclose that the lens was experimental and being evaluated for safety and effectiveness.

Holding

The court recognized the significance of the hospital's involvement in the informed-consent process.

The hospital had undertaken responsibilities through its Institutional Review Board concerning informed consent.

Principle

Although physicians ordinarily have primary responsibility for informed consent, an institution may potentially assume its own responsibility where it undertakes specific regulatory or consent-related duties.

This principle was discussed in Lenahan v. University of Chicago.

Importance

The case is important for determining when liability may extend beyond the treating/research physician to the institution.

12. Dressen v. AstraZeneca AB — Tenth Circuit (2026)

This is an especially important recent case.

Facts

Dressen participated in an experimental COVID-19 vaccine clinical trial.

Her informed-consent documentation stated that AstraZeneca would provide or arrange medical treatment for trial-related illness or injury and indicated that insurance coverage existed for certain trial injuries.

After she suffered serious injuries, AstraZeneca declined her request for compensation and medical care.

She sued for breach of contract and breach of the contractual duty of good faith.

Decision

In July 2026, the Tenth Circuit held that the federal PREP Act's immunity provision could encompass claims for loss, including contract-based damages, but remanded for consideration of whether AstraZeneca had waived immunity through the informed-consent form.

Importance

This is highly significant because it shows that an informed-consent document can potentially do more than prove disclosure.

It may also contain contractual promises.

Thus:

The consent form can potentially become a source of liability rather than merely a defense against liability.

13. Indian Position

India has developed a comparatively strong regulatory framework for compensation of clinical-trial injuries.

The regulatory framework historically centered on Rule 122DAB of the Drugs and Cosmetics Rules, 1945, followed by the 2019 New Drugs and Clinical Trials Rules framework.

The Indian system recognizes that a trial participant who suffers qualifying clinical-trial injury or death can be entitled to:

• medical management;
• financial compensation;
• compensation to nominees in case of death.

Rule 122DAB expressly placed medical-management and compensation expenses on the sponsor.

14. Swasthya Adhikar Manch, Indore v. Union of India

Supreme Court of India

This litigation is one of the most important Indian judicial developments concerning clinical-trial liability.

Facts

A public-interest petition raised concerns regarding:

• clinical-trial deaths;
• serious adverse events;
• informed consent;
• regulatory supervision;
• compensation to trial participants.

The Supreme Court required the government to provide detailed information concerning clinical trials, deaths, adverse effects and compensation.

Significance

The litigation contributed to substantial strengthening of India's regulatory regime.

Government measures subsequently included:

• compensation rules;
• inspection requirements;
• ethics-committee registration;
• stronger clinical-trial oversight.

The Government reported to the Supreme Court that amendments to the Drugs and Cosmetics Rules were introduced concerning compensation, inspections and ethics committees.

Principle

Clinical-trial participants require regulatory protection beyond ordinary contractual consent.

15. Jananeethi v. Union of India

Kerala High Court, 2021

Facts

The litigation sought stronger protection for clinical-trial participants, including:

• comprehensive health insurance;
• medical treatment;
• compensation for injury;
• compensation in case of death.

The court considered the regulatory framework governing sponsors, investigators and clinical trials.

Importance

The case demonstrates the role of constitutional and public-law litigation in enforcing safeguards for research participants.

16. Asif Riaz v. Government of India

Madras High Court

This case involved a participant in a vaccine-related clinical trial.

Principle

The court emphasized that compensation depends upon establishing the necessary causal connection between the clinical-trial intervention and the serious adverse event.

Where the adverse event is not established to have been caused by the trial intervention, compensation cannot automatically be imposed merely because the participant suffered a medical complication.

Conversely, where the serious adverse event is established to be directly attributable to the vaccine/intervention, the sponsor's compensation and treatment obligations can arise.

Importance

The case illustrates the importance of:

causation + regulatory compensation framework.

17. Indian Compensation Framework

Under the clinical-trial compensation regime, qualifying injuries can include those caused by:

• adverse effects of the investigational product;
• protocol violations;
• scientific misconduct;
• negligence;
• failure of the investigational product to provide intended therapeutic effect where required standard care was not provided;
• placebo use in specified circumstances;
• adverse effects of certain concomitant medications;
• injury to a child in utero resulting from parental participation;
• clinical-trial procedures.

The regulatory approach is therefore broader than simply:

“The sponsor was negligent.”

Certain trial-related injuries may trigger compensation because of their connection to the clinical trial itself.

18. Strict or No-Fault Elements in the Indian Model

A significant feature of India's regulatory framework is that compensation is not entirely dependent upon proving traditional negligence.

For example, the regulatory framework recognizes certain adverse effects of investigational products and specified trial-related events as compensable.

This creates a distinction between:

Tort liability

Requires proof such as:

duty → breach → causation → damage

and

Regulatory compensation

May arise from:

qualifying clinical-trial injury → regulatory determination → compensation obligation.

This distinction is extremely important.

19. Sponsor Liability

The sponsor is often the central party in clinical-trial liability.

Responsibilities can include:

• trial design;
• safety monitoring;
• investigator selection;
• regulatory compliance;
• insurance/indemnification;
• adverse-event reporting;
• compensation;
• data integrity;
• protocol compliance.

A sponsor may be liable where harm results from:

• defective trial design;
• inadequate monitoring;
• failure to disclose known risks;
• failure to stop the trial;
• protocol violations;
• investigational-product risks falling within applicable compensation rules.

20. Investigator Liability

The investigator may be liable for:

• inadequate informed consent;
• negligent medical care;
• failure to monitor;
• protocol violations;
• failure to report adverse events;
• failure to protect vulnerable participants;
• failure to withdraw a participant where continuation becomes unsafe.

The investigator's position is particularly important because the participant often interacts directly with the investigator rather than the sponsor.

21. Hospital / Research Institution Liability

A hospital or university may face liability where it:

• negligently supervises the study;
• fails to comply with institutional requirements;
• undertakes informed-consent responsibilities;
• negligently selects investigators;
• inadequately monitors the research;
• violates contractual obligations.

Kus and Lenahan illustrate why institutional responsibility can depend on the particular role undertaken by the hospital.

22. Ethics Committee / IRB Liability

An ethics committee's primary function is participant protection.

Its responsibilities may include:

• reviewing protocols;
• evaluating risks and benefits;
• reviewing informed-consent materials;
• monitoring serious adverse events;
• continuing review;
• protecting vulnerable populations.

However, whether an ethics committee can be sued directly depends heavily upon jurisdiction, statutory immunity, institutional structure and the precise duty alleged.

Therefore:

IRB approval does not automatically immunize investigators or sponsors from liability.

Likewise, IRB approval does not necessarily guarantee that informed consent was legally sufficient.

23. CRO Liability

A Contract Research Organization may perform:

• recruitment;
• monitoring;
• data management;
• pharmacovigilance;
• site management;
• regulatory support.

Where functions are delegated, contractual arrangements become important in determining responsibility.

However:

Delegating a trial function does not necessarily eliminate the sponsor's ultimate regulatory responsibilities.

24. Informed Consent: The Central Doctrine

Informed consent should generally contain information concerning:

Nature

“This is research.”

Purpose

Why the study is being conducted.

Procedures

What will happen to the participant.

Risks

Known and reasonably foreseeable risks.

Benefits

Potential benefits, including the possibility of no direct benefit.

Alternatives

Available alternatives where applicable.

Confidentiality

How research information will be handled.

Compensation

Whether compensation is available.

Injury treatment

Whether medical treatment is available if the participant is injured.

These requirements are reflected in the regulatory framework for human-subject research.

25. Continuing Consent

Informed consent is not necessarily a one-time event.

If a material new risk emerges, researchers may have a duty to:

• inform participants;
• update consent materials;
• obtain renewed consent where required;
• reconsider continuation.

This principle was particularly emphasized in Grimes.

The participant's consent must remain meaningful as the research develops.

26. Clinical Trial Liability and Causation

Causation can be difficult.

Suppose:

Participant receives experimental drug → develops heart condition.

The participant must potentially establish whether:

1. the drug caused the condition;
2. the disease itself caused the condition;
3. another medication caused it;
4. the condition was unrelated.

This is why regulatory systems may distinguish between:

adverse event

and

serious adverse event related to the clinical trial.

The Indian judicial decision in Asif Riaz illustrates this issue: a serious medical event alone does not automatically establish entitlement to compensation; the required causal relationship must be established.

27. Clinical Trial Liability and Product Liability

There can be overlap between:

Clinical-trial liability

Concerned with:

• trial conduct;
• consent;
• monitoring;
• protocol;
• research duties.

Product liability

Concerned with:

• defective product;
• manufacturing defect;
• design defect;
• inadequate warnings.

A participant may potentially pursue both theories where the applicable law permits.

28. Clinical Trial Liability and Contract Law

The informed-consent document may sometimes constitute or contain contractual commitments.

Grimes recognized contractual implications of the research consent arrangement.

Dressen v. AstraZeneca demonstrates the modern significance of this issue: the participant relied upon promises in the consent document concerning treatment and compensation, while the sponsor argued federal immunity. The Tenth Circuit's 2026 decision required consideration of whether the sponsor had waived immunity through the document itself.

Therefore:

A consent form should not automatically be treated as merely a waiver document.

It may contain affirmative promises.

29. Clinical Trial Liability and Vulnerable Participants

Special protections may be required for:

• children;
• pregnant women;
• prisoners;
• persons lacking decision-making capacity;
• economically vulnerable populations;
• persons with serious illnesses;
• populations with limited healthcare alternatives.

Grimes is particularly important because it involved children exposed to lead during non-therapeutic research.

30. Clinical Trial Liability and Placebos

Placebo-controlled trials create a difficult issue.

The legal question is not simply:

“Was a placebo used?”

Instead:

Was placebo use ethically and legally permissible given the availability of established standard care?

Indian clinical-trial compensation rules specifically address certain injuries associated with placebo use where standard care was available but not provided in accordance with the protocol.

31. Clinical Trial Death

Where a participant dies, possible claims may include:

• wrongful death;
• statutory compensation;
• contractual compensation;
• negligence;
• product liability;
• breach of informed consent;
• regulatory compensation.

In India, the regulatory framework expressly provides for compensation to the nominee/legal heir where a clinical-trial-related death satisfies the applicable conditions.

32. Damages

Depending upon the jurisdiction, recoverable damages can potentially include:

Economic damages

• medical expenses;
• rehabilitation;
• lost wages;
• future earning loss;
• care costs.

Non-economic damages

• pain and suffering;
• emotional distress;
• loss of enjoyment of life.

Death claims

• loss of dependency;
• funeral expenses;
• loss suffered by dependants.

Regulatory compensation

May operate independently of ordinary tort damages.

33. Defenses Available to Sponsors and Investigators

A. Adequate informed consent

The participant was fully informed of the relevant risk.

B. Risk was unavoidable

The adverse outcome was a known risk inherent in the investigational intervention.

C. No causation

The trial did not cause the injury.

D. Compliance with protocol

The researchers followed the approved study protocol.

E. Regulatory compliance

The trial complied with applicable regulatory requirements.

F. Statutory immunity

Certain products or circumstances may receive statutory immunity.

The Dressen litigation demonstrates the importance of statutory immunity in pandemic-era vaccine trials.

34. Important Distinction: Consent Is Not a Complete Defense

A participant's consent does not necessarily excuse:

• negligence;
• fraud;
• intentional misconduct;
• protocol violations;
• concealment of material risks;
• regulatory violations.

In fact, research regulations generally prohibit consent documents from simply requiring subjects to waive their legal rights for negligence. The regulatory framework discussed in Grimes specifically recognized this principle.

Thus:

“The participant signed the form” does not automatically mean “the sponsor cannot be liable.”

35. Clinical Trial Liability in India — Practical Framework

For an Indian claim, the following sequence is useful:

1. Participant suffers injury/death

↓

2. Identify clinical trial

↓

3. Identify sponsor/investigator/CRO/institution

↓

4. Determine whether event is trial-related

↓

5. Examine informed consent

↓

6. Examine trial protocol

↓

7. Examine adverse-event investigation

↓

8. Determine causation

↓

9. Ethics Committee / regulatory determination

↓

10. Medical management

↓

11. Compensation

↓

12. Additional civil/constitutional remedies where available

India's rules expressly place medical-management and compensation expenses for qualifying clinical-trial injuries/deaths upon the sponsor.

36. Clinical Trials and Constitutional Rights in India

Clinical-trial disputes can also implicate:

Article 21

Protection of:

• life;
• bodily integrity;
• dignity;
• health;
• autonomy.

Article 14

Relevant where regulatory treatment is arbitrary or discriminatory.

Article 19

Potentially relevant to professional/research freedoms, subject to constitutional limitations.

The Supreme Court's clinical-trial litigation demonstrates the willingness of constitutional courts to examine the adequacy of governmental safeguards protecting research participants.

37. Important Case-Law Summary

38. Key Principles for Examination

The most important principles can be remembered as follows:

1. Clinical research creates special duties

Grimes

2. Adverse outcome alone does not prove negligence

Goodman

3. Experimental risks must be properly disclosed

Slater

4. Multiple trial actors may have separate responsibilities

Lewis

5. Institutional involvement can create institutional duties

Kus

6. Research can generate contractual obligations

Grimes / Dressen

7. Clinical research increasingly includes data and AI issues

Dinerstein

8. Compensation depends on legally sufficient causation

Asif Riaz

9. Indian law provides a specific regulatory compensation framework

Rule 122DAB / 2019 clinical-trial regime

10. Government has a responsibility to protect research participants

Swasthya Adhikar Manch

39. Conclusion

Clinical Trials Liability represents a specialized area of law where medical negligence, informed consent, research ethics, product liability, contract law, regulatory law and constitutional rights intersect.

The most important principle is that participation in a clinical trial does not mean that a participant assumes every possible risk or waives every legal protection.

A participant may voluntarily accept a known and properly disclosed experimental risk, and cases such as Goodman and Slater show why that distinction matters. But where researchers fail to disclose material risks, conduct the trial negligently, violate the approved protocol, misuse participants, or fail to comply with compensation requirements, liability may arise.

Grimes is particularly important because it recognizes that the researcher-subject relationship itself can create legal duties, while Dressen shows how modern informed-consent documents may create affirmative contractual obligations.

In India, the legal position is particularly significant because the regulatory framework provides for medical management and financial compensation for qualifying clinical-trial injuries and deaths, with the sponsor bearing the relevant expenses.

Accordingly, the basic legal formula is:

Proper trial design + valid informed consent + participant monitoring + protocol compliance + adverse-event reporting + regulatory compliance + appropriate medical care + compensation for qualifying trial-related injury = lawful clinical-trial governance.

Where these safeguards fail, clinical-trial liability may arise against the sponsor, investigator, institution, manufacturer or other responsible party, depending upon the applicable law and the particular facts.